Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT02672488 Recruiting - Clinical trials for Hepatocellular Carcinoma

Metformin Plus Sorafenib for Advanced HCC

Start date: December 2015
Phase: Phase 2
Study type: Interventional

Metformin is a widely used oral drug for type 2 diabetes and its antitumor effects have got much more attentions recently. It has been shown that metformin exerts anti-cancer activities in several cancers, including primary liver cancer. In this phase II study, safety and efficacy of the combination of metformin and sorafenib will be evaluated in patients with advanced hepatocellular carcinoma.

NCT ID: NCT02616926 Recruiting - Clinical trials for Hepatocellular Carcinoma

Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma

Start date: December 2015
Phase: N/A
Study type: Interventional

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world. For patients with intermediate HCC (BCLC stage B), transarterial chemoembolization (TACE) has been recommended as the standard therapy in many clinical practice guidelines. The combination of TACE and radiofrequency ablation (RFA) has also been reported as an effective treatment. However, more and more retrospective studies have reported better therapeutic efficacy of hepatic resection than TACE for intermediate HCC. The purpose of this study was to compare the efficacy of hepatic resection versus TACE+RFA for the treatment of intermediate HCC through prospective randomized clinical trial.

NCT ID: NCT02587689 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor

Start date: October 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize (Mucin 1) MUC1 is safe and effective for patients with relapsed or refractory solid tumor.

NCT ID: NCT02586285 Recruiting - Clinical trials for Hepatocellular Carcinoma

Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma

Start date: June 2015
Phase: Phase 1
Study type: Interventional

The aim of this study is to explore the effect of S-Adenosyl Methionine on recurrence after curative resection of Hepatocellular Carcinoma.

NCT ID: NCT02562963 Recruiting - Colorectal Cancer Clinical Trials

Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor

Start date: November 2015
Phase: Phase 1/Phase 2
Study type: Interventional

Natural killer T (NKT) cells are a unique subset of lymphocytes that present a mixed T-NK phenotype. Our hypothesis is that Natural killer T cells may decrease the tumor burden and improve overall survival. The purpose of this study is to determine whether Natural killer T (NKT) cells are effective and safe in the treatment of patients with unresectable advanced solid tumor.

NCT ID: NCT02550613 Recruiting - Clinical trials for Hepatocellular Carcinoma

Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma

Start date: May 2014
Phase: N/A
Study type: Observational

The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients.

NCT ID: NCT02537158 Recruiting - Clinical trials for Hepatocellular Carcinoma

Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection

Start date: August 2015
Phase: N/A
Study type: Interventional

This study is a prospective non-randomized controlled study. The purpose of this study is to evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization (TACE) for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients after radical surgery.

NCT ID: NCT02534961 Recruiting - Clinical trials for Hepatocellular Carcinoma

Prophylactic Antibiotics Before RFA for HCC

Start date: January 2015
Phase: Phase 4
Study type: Interventional

This randomized prospective study aims to investigate whether prophylactic administration of antibiotics has an influence on inflammatory markers, liver function test results, or the incidence of post-procedural infection in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA).

NCT ID: NCT02529761 Recruiting - Clinical trials for Hepatocellular Carcinoma

TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma

Start date: August 2015
Phase: N/A
Study type: Interventional

This multicenter prospective nonrandomized study is to evaluate the efficacy of TACE combined with sorafenib compared with TACE monotherapy in term of overall survival in intermediate-stage HCC.

NCT ID: NCT02525965 Recruiting - Clinical trials for Hepatocellular Carcinoma

The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma

Start date: August 2015
Phase: N/A
Study type: Interventional

Before the surgery, the investigators predict the risk of microvascular invasion (MVI) presence for the early-stage hepatocellular carcinoma according to the nomogram the investigators have created. Patients with a high risk of microvascular invasion were randomly chose to give the treatment of a wide resection margin, which establish an individualized anti-recurrence program based on the high-grade evidence-based medicine.